Vera's strategic positioning centers on an unmet need in immunological diseases with a differentiated mechanism: atacicept is a fully humanized TACI-Fc fusion protein that binds both BAFF and APRIL, representing a dual-pathway approach. The company has secured substantial capital ($800M in combined equity and debt financing) and maintains a strong cash position ($714.6M at year-end 2025), enabling execution through commercialization while advancing a pipeline including MAU868 for BK viremia and VT-109 for B cell mediated autoimmune diseases.
Cyborg Score Rationale
Vera demonstrates strong fundamentals with positive Phase 3 efficacy data, FDA Priority Review, substantial capitalization, and a clear path to commercialization in 2026. The company is pre-revenue but has de-risked its lead program significantly. Key risks include regulatory approval execution, competitive landscape, and post-launch commercialization success.
Top Insights
ORIGIN Phase 3 trial showed atacicept reduced proteinuria by 46% from baseline and 42% vs placebo (p<0.0001), with results published in NEJM and presented at ASN in November 2025
FDA Priority Review and Breakthrough Therapy designation accelerate path to approval; PDUFA decision expected July 7, 2026 with potential mid-2026 U.S. commercial launch
Strong balance sheet with $714.6M cash and completed $800M financing enables multi-year operation and commercial infrastructure build without near-term dilution pressure
Pipeline depth includes MAU868 (BK viremia, Phase 2 complete) and VT-109 (BAFF/APRIL/BCMA triple inhibitor), diversifying revenue potential beyond atacicept
(December 2025) FDA accepted BLA for atacicept and granted Priority Review with July 7, 2026 PDUFA target date
(November 2025) ORIGIN Phase 3 interim data presented at ASN Kidney Week and published in New England Journal of Medicine showing 46% proteinuria reduction
(2025 Full Year) Net loss of $299.6M; completed $800M combined equity and debt financing; held $714.6M in cash
Open the full interactive Vera Therapeutics, Inc. report
30-page strategic research, 15-min analyst-debate audio briefing, full Cyborg Score breakdown across 11 dimensions.